LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
December 20 2021 - 7:00AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage
biotechnology company focused on developing its proprietary
Gammabody™ platform of bispecific gamma delta T cell engagers
(bsTCEs) to transform the treatment of cancer, today announced that
Stephen Hurly, chief executive officer, will present a corporate
overview at the 40th Annual J.P. Morgan Healthcare Conference
on Wednesday, Jan. 12, 2021 at 1:30 p.m. EST.
“We are excited to round out a transformative
2021 and eager to kick-off what promises to be an exciting 2022 for
LAVA,” said Stephen Hurly, president and chief executive officer.
“With both of our lead liquid and solid tumor
Gammabody™ programs actively recruiting patients, our focus is
on carrying out our mission to rapidly develop new cancer
treatments that leverage gamma delta T cells to save patients’
lives.”
Access to the recording will be available under
the "Events" tab on the investor relations section of the LAVA
Therapeutics website
at: https://ir.lavatherapeutics.com/news-events/events.
About LAVA TherapeuticsLAVA
Therapeutics N.V. is a clinical-stage biotechnology company
utilizing its proprietary Gammabody™ platform to develop a
portfolio of bispecific gamma delta T cell engagers (gamma delta
bsTCEs) for the potential treatment of solid tumors and
hematological malignancies. The company’s innovative approach
utilizes bispecific antibodies engineered to selectively kill
cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector
functions upon cross-linking to tumor associated antigens. A Phase
1/2a clinical study evaluating LAVA-051 in patients with certain
hematological malignancies is currently enrolling (NCT04887259).
The company currently anticipates data from the Phase 1 dose
escalation phase of the study in the first half of 2022 with top
line clinical data from the Phase 2a expansion cohorts expected in
the second half of 2022. The company is actively recruiting
patients in a Phase 1/2a clinical study to evaluate LAVA-1207 in
patients with prostate cancer. For more information, please visit
www.lavatherapeutics.com and follow us on LinkedIn and Twitter.
LAVA’s Cautionary Note on
Forward-Looking StatementsThis press release contains
forward-looking statements, including in respect of the company’s
anticipated growth and clinical developments plans, including the
timing of clinical trials. Words such as “anticipate,” “believe,”
“could,” “will,” “may,” “expect,” “should,” “plan,” “intend,”
“estimate,” “potential” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on LAVA’s expectations
and assumptions as of the date of this press release and are
subject to various risks and uncertainties that may cause actual
results to differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the preclinical data,
clinical development and scope of clinical trials, and the
potential use of our product candidates to treat various tumor
targets. Many factors, risks and uncertainties may cause
differences between current expectations and actual results
including, among other things, the timing and results of our
research and development programs and preclinical and clinical
trials, our ability to obtain regulatory approval for and
commercialize our product candidates, our ability to leverage our
initial programs to develop additional product candidates using our
Gammabody™ platform, and the failure of LAVA’s collaborators
to support or advance collaborations or our product candidates. In
addition, the COVID-19 pandemic may disrupt our business and that
of the third parties on which we depend, including delaying or
otherwise disrupting our clinical trials and preclinical studies,
manufacturing and supply chain, or impairing employee productivity.
LAVA assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
CONTACTEdward SmithChief Financial
Officerir@lavatherapeutics.com
Catherine
Day+1-917-763-2709catherine@newdaybioconsulting.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Sep 2023 to Sep 2024